Cassava Sciences Completes Patient Enrollment For Pivotal Phase 3 Clinical Trial Of Oral Simufilam In Alzheimer's Disease
Portfolio Pulse from Benzinga Newsdesk
Cassava Sciences has completed patient enrollment for a pivotal Phase 3 clinical trial of oral Simufilam in Alzheimer's disease with 804 patients. A second Phase 3 trial is expected to complete enrollment by Q4 2023, targeting approximately 1,100 patients.
October 02, 2023 | 1:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cassava Sciences' completion of patient enrollment for the Phase 3 trial of Simufilam could potentially accelerate the drug's approval process, potentially positively impacting the company's stock.
The completion of patient enrollment for the Phase 3 trial of Simufilam is a significant milestone for Cassava Sciences. This could potentially accelerate the drug's approval process, which could lead to increased revenues for the company and a potential boost in the company's stock price. However, the final impact will depend on the trial results.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100